Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-552 in Mild Alzheimer's Disease
2022-501918-55-00Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of SDI-118 in Alzheimer's disease (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline in ADAS-Cog 14 score at Week 12. Started Jun 2023; status: completed.
02
Drugs
SDI-118
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-501918-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501918-55-00.